AlphaMab Oncology Announces First Patient Dosed in Phase I Trial for JSKN027

Stock News

Mar 16

AlphaMab Oncology (09966) has announced that the first patient has been successfully dosed in a Phase I clinical study (Study Number: JSKN027-101) of JSKN027, the company's independently developed PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC). The trial is evaluating JSKN027 for the treatment of advanced malignant solid tumors. JSKN027 represents the fifth ADC candidate from the company to enter clinical studies and is the first PD-L1/VEGFR2 bispecific ADC globally to advance to this stage. Due to its multiple mechanisms of action, including cytotoxic killing, anti-angiogenesis, and immune regulation, JSKN027 holds the potential to offer new therapeutic options for various solid tumors. JSKN027-101 is an open-label, multicenter, Phase I clinical study conducted in subjects with advanced malignant solid tumors. The trial consists of two phases: dose escalation and dose expansion. Its primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JSKN027 in patients with advanced malignant solid tumors, and to determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1194674893"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194674893\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194674893?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194674893","market":"us","top_or_hot":-1,"title":"AlphaMab Oncology Announces First Patient Dosed in Phase I Trial for JSKN027","media":"Stock News","content":"<p>AlphaMab Oncology (09966) has announced that the first patient has been successfully dosed in a Phase I clinical study (Study Number: JSKN027-101) of JSKN027, the company's independently developed PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC). The trial is evaluating JSKN027 for the treatment of advanced malignant solid tumors. JSKN027 represents the fifth ADC candidate from the company to enter clinical studies and is the first PD-L1/VEGFR2 bispecific ADC globally to advance to this stage. Due to its multiple mechanisms of action, including cytotoxic killing, anti-angiogenesis, and immune regulation, JSKN027 holds the potential to offer new therapeutic options for various solid tumors. JSKN027-101 is an open-label, multicenter, Phase I clinical study conducted in subjects with advanced malignant solid tumors. The trial consists of two phases: dose escalation and dose expansion. Its primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JSKN027 in patients with advanced malignant solid tumors, and to determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AlphaMab Oncology Announces First Patient Dosed in Phase I Trial for JSKN027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlphaMab Oncology Announces First Patient Dosed in Phase I Trial for JSKN027\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-16 20:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AlphaMab Oncology (09966) has announced that the first patient has been successfully dosed in a Phase I clinical study (Study Number: JSKN027-101) of JSKN027, the company's independently developed PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC). The trial is evaluating JSKN027 for the treatment of advanced malignant solid tumors. JSKN027 represents the fifth ADC candidate from the company to enter clinical studies and is the first PD-L1/VEGFR2 bispecific ADC globally to advance to this stage. Due to its multiple mechanisms of action, including cytotoxic killing, anti-angiogenesis, and immune regulation, JSKN027 holds the potential to offer new therapeutic options for various solid tumors. JSKN027-101 is an open-label, multicenter, Phase I clinical study conducted in subjects with advanced malignant solid tumors. The trial consists of two phases: dose escalation and dose expansion. Its primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JSKN027 in patients with advanced malignant solid tumors, and to determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1194674893","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194674893","pubTimestamp":1773665069,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"AlphaMab Oncology (09966) has announced that the first patient has been successfully dosed in a Phase I clinical study (Study Number: JSKN027-101) of JSKN027, the company's independently developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","09966":"康宁杰瑞制药-B","BK1574":"生物医药B类股"},"translate_title":"康宁杰瑞肿瘤宣布JSKN027 I期试验首例患者给药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":1},"content_text":"AlphaMab Oncology (09966) has announced that the first patient has been successfully dosed in a Phase I clinical study (Study Number: JSKN027-101) of JSKN027, the company's independently developed PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC). The trial is evaluating JSKN027 for the treatment of advanced malignant solid tumors. JSKN027 represents the fifth ADC candidate from the company to enter clinical studies and is the first PD-L1/VEGFR2 bispecific ADC globally to advance to this stage. Due to its multiple mechanisms of action, including cytotoxic killing, anti-angiogenesis, and immune regulation, JSKN027 holds the potential to offer new therapeutic options for various solid tumors. JSKN027-101 is an open-label, multicenter, Phase I clinical study conducted in subjects with advanced malignant solid tumors. The trial consists of two phases: dose escalation and dose expansion. Its primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JSKN027 in patients with advanced malignant solid tumors, and to determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}